But what will be the consequences of these difficulties for smaller companies in the biotech industry as a whole?
But what will be the consequences of these difficulties for smaller companies in the biotech industry as a whole? “In the first half of 2024, we suspect many small biotech companies may end up being delisted or become shells into which other companies reverse merge. We also anticipate a flurry of M&A activity, especially with big pharma companies acquiring some larger biotechs, and there may also be a flurry of partnering activity between smaller biotechs and either larger biotechs or pharma companies,” said Tucker.